News >

Standard of Care Continues to Shift in RCC

Danielle Bucco
Published: Friday, May 11, 2018

Toni K. Choueiri, MD

Toni K. Choueiri, MD
The standard of care for patients with renal cell carcinoma (RCC) continues to change as novel therapies and combinations rapidly get approved, says Toni K. Choueiri, MD.

For example, the December 2017 FDA approval of cabozantinib (Cabometyx) was based off of practice-changing data from the phase II CABOSUN trial, in which the multikinase inhibitor reduced the risk of progression or death by 52% compared with sunitinib (Sutent). Additionally, the median progression-free survival was 8.6 months with cabozantinib versus 5.3 months for sunitinib (HR, 0.48; 95% CI, 0.31-0.74; P = .0008).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication